-
Je něco špatně v tomto záznamu ?
Routine Spironolactone in Acute Myocardial Infarction
SS. Jolly, MA. d'Entremont, B. Pitt, SF. Lee, R. Mian, J. Tyrwhitt, S. Kedev, G. Montalescot, JH. Cornel, G. Stanković, R. Moreno, RF. Storey, TD. Henry, SR. Mehta, M. Bossard, P. Kala, R. Bhindi, B. Zafirovska, PJ. Devereaux, J. Eikelboom, JA....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie
NLK
ProQuest Central
od 1980-01-03 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
PubMed
39555814
DOI
10.1056/nejmoa2405923
Knihovny.cz E-zdroje
- MeSH
- antagonisté mineralokortikoidních receptorů * terapeutické užití škodlivé účinky MeSH
- cévní mozková příhoda mortalita MeSH
- dvojitá slepá metoda MeSH
- infarkt myokardu * mortalita farmakoterapie MeSH
- Kaplanův-Meierův odhad MeSH
- kardiovaskulární nemoci mortalita prevence a kontrola MeSH
- koronární angioplastika MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- spironolakton * terapeutické užití škodlivé účinky MeSH
- srdeční selhání * farmakoterapie mortalita MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain. METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with myocardial infarction who had undergone percutaneous coronary intervention to receive either spironolactone or placebo and either colchicine or placebo. The results of the spironolactone trial are reported here. The two primary outcomes were a composite of death from cardiovascular causes or new or worsening heart failure, evaluated as the total number of events; and a composite of the first occurrence of myocardial infarction, stroke, new or worsening heart failure, or death from cardiovascular causes. Safety was also assessed. RESULTS: We enrolled 7062 patients at 104 centers in 14 countries; 3537 patients were assigned to receive spironolactone and 3525 to receive placebo. At the time of our analyses, the vital status was unknown for 45 patients (0.6%). For the first primary outcome, there were 183 events (1.7 per 100 patient-years) in the spironolactone group as compared with 220 events (2.1 per 100 patient-years) in the placebo group over a median follow-up period of 3 years (hazard ratio adjusted for competing risk of death from noncardiovascular causes, 0.91; 95% confidence interval [CI], 0.69 to 1.21; P = 0.51). With respect to the second primary outcome, an event occurred in 280 of 3537 patients (7.9%) in the spironolactone group and 294 of 3525 patients (8.3%) in the placebo group (hazard ratio adjusted for competing risk, 0.96; 95% CI, 0.81 to 1.13; P = 0.60). Serious adverse events were reported in 255 patients (7.2%) in the spironolactone group and 241 (6.8%) in the placebo group. CONCLUSIONS: Among patients with myocardial infarction, spironolactone did not reduce the incidence of death from cardiovascular causes or new or worsening heart failure or the incidence of a composite of death from cardiovascular causes, myocardial infarction, stroke, or new or worsening heart failure. (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).
B P Koirala Institute of Health Sciences Dharan Nepal
Cardiology Department University Hospital La Paz Madrid
Caril and Edyth Lindner Center for Research and Education Christ Hospital Health Network Cincinnati
Centre Hospitalier Universitaire de Sherbrooke Sherbrooke QC Canada
Clinical Hospital Tetovo Tetovo North Macedonia
Department of Cardiology Peninsula Health Frankston VIC Australia
Department of Medicine University of Saskatchewan Moose Jaw Canada
Division of Clinical Medicine University of Sheffield Sheffield United Kingdom
Dutch Network for Cardiovascular Research Utrecht the Netherlands
Hamilton Health Sciences Hamilton ON Canada
Institut za Kardiovaskularne Bolesti Dedinje Belgrade Belgrade Serbia
London Health Sciences Centre University of Western Ontario London Canada
Northwest Clinics Alkmaar the Netherlands
Peninsula Clinical School Central Clinical School Monash University Melbourne VIC Australia
Population Health Research Institute McMaster University Hamilton ON Canada
Quebec Heart Lung Institute Laval University Quebec QC Canada
Radboud University Medical Center Nijmegen the Netherlands
Southlake Regional Health Centre Newmarket University of Toronto Toronto
St Mary's Hospital Kitchener ON Canada
University Clinical Center of Serbia and Faculty of Medicine University of Belgrade Belgrade
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009888
- 003
- CZ-PrNML
- 005
- 20250429134756.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1056/NEJMoa2405923 $2 doi
- 035 __
- $a (PubMed)39555814
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jolly, Sanjit S $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada $1 https://orcid.org/0000000323292504
- 245 10
- $a Routine Spironolactone in Acute Myocardial Infarction / $c SS. Jolly, MA. d'Entremont, B. Pitt, SF. Lee, R. Mian, J. Tyrwhitt, S. Kedev, G. Montalescot, JH. Cornel, G. Stanković, R. Moreno, RF. Storey, TD. Henry, SR. Mehta, M. Bossard, P. Kala, R. Bhindi, B. Zafirovska, PJ. Devereaux, J. Eikelboom, JA. Cairns, MK. Natarajan, JD. Schwalm, SK. Sharma, W. Tarhuni, D. Conen, S. Tawadros, S. Lavi, V. Asani, D. Topic, WJ. Cantor, OF. Bertrand, A. Pourdjabbar, S. Yusuf, CLEAR investigators, CLEAR Investigators
- 520 9_
- $a BACKGROUND: Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain. METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with myocardial infarction who had undergone percutaneous coronary intervention to receive either spironolactone or placebo and either colchicine or placebo. The results of the spironolactone trial are reported here. The two primary outcomes were a composite of death from cardiovascular causes or new or worsening heart failure, evaluated as the total number of events; and a composite of the first occurrence of myocardial infarction, stroke, new or worsening heart failure, or death from cardiovascular causes. Safety was also assessed. RESULTS: We enrolled 7062 patients at 104 centers in 14 countries; 3537 patients were assigned to receive spironolactone and 3525 to receive placebo. At the time of our analyses, the vital status was unknown for 45 patients (0.6%). For the first primary outcome, there were 183 events (1.7 per 100 patient-years) in the spironolactone group as compared with 220 events (2.1 per 100 patient-years) in the placebo group over a median follow-up period of 3 years (hazard ratio adjusted for competing risk of death from noncardiovascular causes, 0.91; 95% confidence interval [CI], 0.69 to 1.21; P = 0.51). With respect to the second primary outcome, an event occurred in 280 of 3537 patients (7.9%) in the spironolactone group and 294 of 3525 patients (8.3%) in the placebo group (hazard ratio adjusted for competing risk, 0.96; 95% CI, 0.81 to 1.13; P = 0.60). Serious adverse events were reported in 255 patients (7.2%) in the spironolactone group and 241 (6.8%) in the placebo group. CONCLUSIONS: Among patients with myocardial infarction, spironolactone did not reduce the incidence of death from cardiovascular causes or new or worsening heart failure or the incidence of a composite of death from cardiovascular causes, myocardial infarction, stroke, or new or worsening heart failure. (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a spironolakton $x terapeutické užití $x škodlivé účinky $7 D013148
- 650 12
- $a infarkt myokardu $x mortalita $x farmakoterapie $7 D009203
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a antagonisté mineralokortikoidních receptorů $x terapeutické užití $x škodlivé účinky $7 D000451
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a srdeční selhání $x farmakoterapie $x mortalita $7 D006333
- 650 _2
- $a koronární angioplastika $7 D062645
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a kardiovaskulární nemoci $x mortalita $x prevence a kontrola $7 D002318
- 650 _2
- $a cévní mozková příhoda $x mortalita $7 D020521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a d'Entremont, Marc-André $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada $u Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
- 700 1_
- $a Pitt, Bertram $u University of Michigan, Ann Arbor
- 700 1_
- $a Lee, Shun Fu $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Mian, Rajibul $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Tyrwhitt, Jessica $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- 700 1_
- $a Kedev, Sasko $u Medical Faculty, University Clinic of Cardiology, University Ss. Cyril and Methodius, Skopje, North Macedonia
- 700 1_
- $a Montalescot, Gilles $u Sorbonne University, ACTION Study Group, Centre Hospitalier Universitaire Pitié-Salpêtrière Assistance Publique-Hôpitaux de Paris, Paris
- 700 1_
- $a Cornel, Jan H $u Dutch Network for Cardiovascular Research, Utrecht, the Netherlands $u Radboud University Medical Center, Nijmegen, the Netherlands $u Northwest Clinics, Alkmaar, the Netherlands
- 700 1_
- $a Stanković, Goran $u University Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade
- 700 1_
- $a Moreno, Raul $u Cardiology Department, University Hospital La Paz, Madrid
- 700 1_
- $a Storey, Robert F $u NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom $u Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom
- 700 1_
- $a Henry, Timothy D $u Caril and Edyth Lindner Center for Research and Education, Christ Hospital Health Network, Cincinnati
- 700 1_
- $a Mehta, Shamir R $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Bossard, Matthias $u Cardiology Division, Heart Center, Luzerner Kantonsspital, and Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
- 700 1_
- $a Kala, Petr $u University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Bhindi, Ravinay $u Department of Cardiology, Peninsula Health, Frankston, VIC, Australia $u Peninsula Clinical School, Central Clinical School, Monash University, Melbourne, VIC, Australia
- 700 1_
- $a Zafirovska, Biljana $u Medical Faculty, University Clinic of Cardiology, University Ss. Cyril and Methodius, Skopje, North Macedonia
- 700 1_
- $a Devereaux, P J $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada $1 https://orcid.org/000000032935637X
- 700 1_
- $a Eikelboom, John $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Cairns, John A $u University of British Columbia and Centre for Cardiovascular Innovation, Vancouver Coastal Health, Vancouver, Canada
- 700 1_
- $a Natarajan, Madhu K $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Schwalm, J D $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Sharma, Sanjib K $u B.P. Koirala Institute of Health Sciences, Dharan, Nepal
- 700 1_
- $a Tarhuni, Wadea $u Department of Medicine, University of Saskatchewan, Moose Jaw, Canada
- 700 1_
- $a Conen, David $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Tawadros, Sarah $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- 700 1_
- $a Lavi, Shahar $u London Health Sciences Centre, University of Western Ontario, London, Canada
- 700 1_
- $a Asani, Valon $u Clinical Hospital Tetovo, Tetovo, North Macedonia
- 700 1_
- $a Topic, Dragan $u Institut za Kardiovaskularne Bolesti Dedinje-Belgrade, Belgrade, Serbia
- 700 1_
- $a Cantor, Warren J $u Southlake Regional Health Centre, Newmarket, University of Toronto, Toronto
- 700 1_
- $a Bertrand, Olivier F $u Quebec Heart-Lung Institute, Laval University, Quebec, QC, Canada
- 700 1_
- $a Pourdjabbar, Ali $u St. Mary's Hospital, Kitchener, ON, Canada
- 700 1_
- $a Yusuf, Salim $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- 710 2_
- $a CLEAR investigators
- 710 2_
- $a CLEAR Investigators
- 773 0_
- $w MED00003517 $t The New England journal of medicine $x 1533-4406 $g Roč. 392, č. 7 (2025), s. 643-652
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39555814 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134751 $b ABA008
- 999 __
- $a ok $b bmc $g 2311336 $s 1246969
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 392 $c 7 $d 643-652 $e 20241117 $i 1533-4406 $m The New England journal of medicine $n N Engl J Med $x MED00003517
- LZP __
- $a Pubmed-20250415
